Animal experiments have shown that TZD drugs indirectly regulate the expression of UAT and URAT1 mRNA by improving IR and reducing blood insulin levels, thereby reducing hyperuricemia caused by hyperinsulinemia. This evidence concerns the gene SLC22A12 and hyperinsulinism.